TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.120nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.120nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.180nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.180nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.280nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.280nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.300nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.340nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.340nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.400nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.400nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.400nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.400nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.420nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.420nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.5nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.5nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.530nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.530nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.710nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.710nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.800nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.800nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.820nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.820nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
Affinity DataIC50: 0.900nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.10nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.10nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.20nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.20nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.40nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.40nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:The phosphodiesterase assay was developed using the LANCE cAMP kit
(PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1%
BSA, and 1....More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMAssay Description:The phosphodiesterase assay was developed using the LANCE® cAMP kit (PerkinElmer). The assay buffer contained HBSS with 5 mM HEPES, 0.1% BSA, and 1.5...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMpH: 7.4Assay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE from Perkin Elmer). This co...More data for this Ligand-Target Pair